Literature DB >> 24099981

A meta-analysis of treating acute traumatic brain injury with calcium channel blockers.

Gang-Zhu Xu1, Mao-De Wang, Kai-Ge Liu, Yin-An Bai, Wei Wu, Wen Li.   

Abstract

The purpose of this systematic review was to evaluate and meta-analyse the current evidence for the use of calcium channel blockers (CCBs) in the treatment of acute traumatic brain injury (TBI) and traumatic subarachnoid haemorrhage (tSAH). A systematic search of clinical trials.gov, Cochrane library databases, EMBASE, MEDLINE, Web of science search and WHO trial registry, plus hand-searching of grey literature, was undertaken in March 2013. Two reviewers independently extracted the data using a pre-defined data extraction form. RevMan 5 software was used to synthesise data and calculate the risk ratio (RR) based on event rates as well as the 95% confidence interval (CI). Finally, nine RCTs with a total of 2182 patients were included. Meta-analysis showed that there was no difference between CCBs and control groups for rates of mortality (n=1337, 5 RCTs, RR 0.93 CI 0.77-1.12). In a subgroup tSAH analysis, the difference was not significant (n=389, 2 RCTs, RR 0.73 CI 0.53-1.02). There were slightly fewer unfavourable outcomes in the treatment group, but the difference was not statistically significant (n=2101, 8 RCTs, RR 0.90 CI 0.76-1.08). In the subgroup tSAH analysis, again, the difference did not reach statistical significance (n=1074, 5 RCTs, RR 0.95 CI 0.73-1.24). It seems that larger, well-designed RCTs are necessary in order to ascertain any clinical benefit CCBs may or may not have for the treatment of acute TBI. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute traumatic brain injury; Calcium channel blockers; Meta-analysis; Traumatic subarachnoid haemorrhage

Mesh:

Substances:

Year:  2013        PMID: 24099981     DOI: 10.1016/j.brainresbull.2013.09.011

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  4 in total

1.  Diltiazem Promotes Regenerative Axon Growth.

Authors:  Eric A Huebner; Stéphane Budel; Zhaoxin Jiang; Takao Omura; Tammy Szu-Yu Ho; Lee Barrett; Janie S Merkel; Luis M Pereira; Nick A Andrews; Xingxing Wang; Bhagat Singh; Kush Kapur; Michael Costigan; Stephen M Strittmatter; Clifford J Woolf
Journal:  Mol Neurobiol       Date:  2018-09-19       Impact factor: 5.590

2.  Efficacy of Simultaneous Administration of Nimodipine, Progesterone, and Magnesium Sulfate in Patients with Severe Traumatic Brain Injury: A Randomized Controlled Trial.

Authors:  Ali Abdoli; Farshid Rahimi-Bashar; Saadat Torabian; Sepideh Sohrabi; Hamid Reza Makarchian
Journal:  Bull Emerg Trauma       Date:  2019-04

3.  Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI.

Authors:  Alexander Morin; Benoit Mouzon; Scott Ferguson; Daniel Paris; Nicole Saltiel; Carlyn Lungmus; Mike Mullan; Fiona Crawford
Journal:  Front Aging Neurosci       Date:  2018-10-11       Impact factor: 5.750

4.  Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI.

Authors:  Alexander Morin; Benoit Mouzon; Scott Ferguson; Daniel Paris; Mackenzie Browning; William Stewart; Mike Mullan; Fiona Crawford
Journal:  Acta Neuropathol Commun       Date:  2020-10-19       Impact factor: 7.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.